RÉFÉRENCES

* Durée d’utilisation recommandée : Utiliser pendant une semaine au maximum. Consulter un professionnel de la santé si les symptômes de troubles digestifs (p. ex. diarrhée) s’aggravent ou persistent pendant plus de trois jours.

  1. Swidsinski, A., Loening-Baucke, V., Verstraelen, H., Osowska, S., & Doerffel, Y. (2008). Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology, 135(2), 568-579.
  2. Buts, J.P., Bernasconi, P., Van Craynest, M.P., Maldague, P., & De Meyer, R. (1986). Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatric Research, 20, 192-196.
  3. Klein, S.M., Elmer, G.W., McFarland, L.V., Surawicz, C.M., & Levy, R.H. (1993). Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers. Pharmaceutical Research, 10, 1615-1619.
  4. Szajewska, H. & Kołodziej, M. (2015). Systematic review with meta‐analysis: Saccharomyces boulardii in the prevention of antibiotic‐associated diarrhoea. Alimentary Pharmacology & Therapeutics, 42(7), 793-801.
  5. Kotowska, M., Albrecht, P., & Szajewska, H. (2005). Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacology & Therapeutics, 21, 583-590.
  6. Villarruel, G., Rubio, D.M., Lopez, F., Cintioni, J., Gurevech, R., et al. (2007). Saccharomyces boulardii in acute childhood diarrhoea: a randomized, placebo‐controlled study. Acta Paediatrica, 96(4), 538-541.
  7. Blehaut, H., Massot, J., Elmer, G.W., & Levy, R.H. (1989). Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharmaceutics & Drug Disposition, 10(4), 353-364.
  8. Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food (2002) Guidelines for the Evaluation of Probiotics in Food. London Ontario, Canada: FAO/WHO.
  9. IMS Data 2017.
  10. Health Canada. (2015, May) Probiotics (Monograph). Retrieved from www.hc-sc.gc.ca
  11. Dinleyici, E.C., Eren, M., Ozen, M., Yargic, Z.A., & Vandenplas, Y. (2012). Effectiveness and safety of Saccharomyces boulardii for acute infectious diarrhea. Expert Opinion on Biological Therapy, 12(4), 395-410.
  12. Neut, C., Mahieux, S., & Dubreuil, L. J. (2017). Antibiotic susceptibility of probiotic strains: Is it reasonable to combine probiotics with antibiotics?. Medecine et maladies infectieuses, 47(7), 477-483.
  13. Kabbani, T. A., Pallav, K., Dowd, S. E., Villafuerte-Galvez, J., Vanga, R. R., et al. (2017). Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers. Gut Microbes, 1, 17-32.
  14. Panda S et al. Short-term effect of antibiotics on human gut microbiota. PLoS One 2014; 9: e95476.
  15. Hickson M et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007; 335: 80
  16. † 2018 IQVIA MIDAS®, 2019 Nielson data Q1 #1 sales in class=Non-bacterial probiotics (yeast-based probiotics)